- Report
- July 2024
- 124 Pages
Saudi Arabia
From €2730EUR$2,999USD£2,318GBP
- Report
- July 2024
- 136 Pages
Turkey
From €2730EUR$2,999USD£2,318GBP
- Report
- July 2024
- 128 Pages
Canada
From €2730EUR$2,999USD£2,318GBP
- Report
- July 2024
- 140 Pages
France
From €2730EUR$2,999USD£2,318GBP
- Report
- July 2024
- 138 Pages
Brazil
From €2730EUR$2,999USD£2,318GBP
- Report
- July 2024
- 128 Pages
Italy
From €2730EUR$2,999USD£2,318GBP
- Report
- July 2024
- 133 Pages
Spain
From €2730EUR$2,999USD£2,318GBP
- Report
- May 2023
- 132 Pages
India
From €2730EUR$2,999USD£2,318GBP
- Report
- August 2022
- 120 Pages
Global
From €4096EUR$4,500USD£3,479GBP
- Report
- October 2022
- 138 Pages
Global
From €4050EUR$4,450USD£3,440GBP
- Report
- April 2025
- 70 Pages
Japan
From €4323EUR$4,750USD£3,672GBP
- Report
- February 2024
- 70 Pages
United States
From €4323EUR$4,750USD£3,672GBP
- Report
- February 2024
- 70 Pages
China
From €4323EUR$4,750USD£3,672GBP
- Report
- February 2024
- 70 Pages
Iran
From €4323EUR$4,750USD£3,672GBP
- Report
- February 2024
- 70 Pages
Asia Pacific
From €4323EUR$4,750USD£3,672GBP
- Report
- February 2024
- 70 Pages
Thailand
From €4323EUR$4,750USD£3,672GBP
- Report
- February 2024
- 70 Pages
Philippines
From €4323EUR$4,750USD£3,672GBP
- Report
- February 2024
- 70 Pages
Oman
From €4323EUR$4,750USD£3,672GBP
- Report
- February 2024
- 75 Pages
Canada
From €4323EUR$4,750USD£3,672GBP
- Report
- February 2024
- 90 Pages
Asia Pacific
From €4323EUR$4,750USD£3,672GBP

The Antidiabetic market is a subset of Endocrine and Metabolic Disorders Drugs, which are used to treat a variety of conditions related to hormones and metabolism. Antidiabetic drugs are used to treat diabetes, a chronic condition in which the body does not produce or properly use insulin. These drugs can help control blood sugar levels, reduce the risk of complications, and improve quality of life. Common antidiabetic drugs include insulin, sulfonylureas, biguanides, thiazolidinediones, and meglitinides.
Some companies in the Antidiabetic market include Novo Nordisk, Sanofi, Eli Lilly, Merck, and Boehringer Ingelheim. These companies produce a variety of antidiabetic drugs, including insulin, oral medications, and combination products. Show Less Read more